The latest generation of cardiovascular stents could dramatically improve on current drug-eluting stent platforms – with better safety profiles and improved healing – but the barriers to entry at FDA could prevent these products from seeing the light of day, some cardiologists warn.
At major cardio meetings this month, stent makers, both start-ups and traditional market leaders, showcased data on several next-gen systems – from stents with biodegradable polymers or polymer-free stents to...